PIK3CD and post-transplant lymphoproliferative disease: In preclinical models, we have previously demonstrated that PI3K pathway inhibition is a rational therapeutic target for EBV+ PTLD (Furukawa et al., 2013; Hatton et al., 2013; Sang et al., 2019); our data here suggest that one mechanism by which this works is by reducing miR-155 expression.